250 words) 22 Daptomycin binds to bacterial cell membranes and disrupts essential cell envelope processes 23 leading to cell death. Bacteria respond to daptomycin by altering their cell envelopes to either 24 decrease antibiotic binding to the membrane or by diverting binding away from vulnerable septal 25 targets to remodeled anionic phospholipid membrane patches. In Enterococcus faecalis, 26 daptomycin resistance is typically coordinated by the three-component cell-envelope-stress- 27 response system, LiaFSR. Here, studying a clinical strain of multidrug-resistant Enterococcus 28 faecium containing alleles associated with activation of the LiaFSR signaling pathway, we found 29 that specific environments selected for different evolutionary trajectories leading to high-level 30 daptomycin resistance. Planktonic environments favored pathways that increased cell surface 31 charge via yvcRS upregulation of dltABCD and mprF, causing a reduction in daptomycin 32 binding. Alternatively, environments favoring complex structured communities, including 33 biofilms, evolved both diversion and repulsion strategies via divIVA and oatA mutations, 34 respectively. Both environments subsequently converged on cardiolipin synthase (cls) mutations, 35 suggesting the importance of membrane modification across strategies. Our findings indicate that 36 E. faecium can evolve diverse evolutionary trajectories to daptomycin resistance that are shaped 37 by the environment to produce a combination of resistance strategies. The accessibility of 38 multiple and different biochemical pathways simultaneously suggests that the outcome of 39 daptomycin exposure results in a polymorphic population of resistant phenotypes making E. 40 faecium a recalcitrant pathogen. 41 42 43 44 48 enterococci (VRE) cause approximately 1,300 deaths annually with the number of infections 49 increasing substantially over the last 15 years (1). The Infectious Disease Society of America has 50 listed E. faecium (Efm) among the no 'ESKAPE' pathogens (Enterococcus faecium, 51 Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas 52 aeruginosa, Enterobacter spp.) for which there is an urgent need for new therapies (2). Efm 53 accounts for a significant amount of enterococcal health-care-associated infections, particularly 54in severely immunocompromised patients. Efm strains that are resistant to all anti-enterococcal 55 antibiotics have been widely described (3-6), making these infections untreatable in certain 56 scenarios (1, 3-5, 7, 8). 57 DAP is a bactericidal cyclic lipopeptide antibiotic approved in 2003 and used widely as a 58 "rescue" drug against MDR Gram-positive organisms such as Staphylococcus aureus, Efm and 59 Enterococcus faecalis (Efc) (4, 9, 10). While the DAP mechanism-of-action remains unclear, 60 DAP acts in a calcium-dependent-manner, where the DAP:Ca +2 complex binds to the cell 61 membrane (CM) in a phosphatidylglycerol-dependent manner with high avidity for division 62 septa. DAP binding has ...